Comprehensive PGx Test: Revolutionizing Personalized Medicine
The Comprehensive Cardio PGx Test is a state-of-the-art solution that integrates precision medicine in cardiovascular disease management. By analyzing genetic variations, this test identifies predispositions to cardiovascular conditions, such as congestive heart failure, cardiomyopathy, atherosclerotic cardiovascular disease, and inherited heart disorders. Additionally, it uncovers pharmacogenomic markers to optimize treatments, minimize side effects, and proactively manage risks. For individuals and clinicians alike, this test serves as a personalized blueprint for individuals and clinicians alike to improve heart health and enhance treatment outcomes.
1. Who Should Take the Comprehensive Cardio PGx Test?
This test is ideal for individuals who:
-
- Are on Cardiovascular Medications: This is tailored for those taking or considering statins, beta-blockers, ACE inhibitors, blood thinners, or other heart medications.
- Have a History of Drug Side Effects: Designed for patients who have experienced adverse reactions, inefficacy, or challenges with current cardiovascular medications.
- Are at Risk for Cardiovascular Disease: Beneficial for individuals with a family history of heart conditions or those seeking to manage potential genetic predispositions.
- Require Complex Drug Regimens: Supports patients with multiple cardiovascular conditions, ensuring effective polypharmacy strategies.
- Seek Personalized Treatment Plans: Offers tailored therapies for maximum efficacy and minimal side effects based on genetic insights.
- Are Under Healthcare Supervision: Supports clinicians adopting heart genetic testing and precision medicine approaches for better patient outcomes.
2. Why is This Test Important?
Chronic illnesses are leading causes of death worldwide. Despite medical advancements, variability in drug response often leads to treatment failures or adverse drug reactions. These variations are influenced by genetic factors critical to drug metabolism and efficacy.
Key Benefits of the Test:
- Avoid Incorrect Medications: Ensures appropriate prescriptions by leveraging genetic insights to prevent ineffective treatments.
- Prevent Adverse Drug Reactions (ADRs): Identifies genetic variations that could trigger harmful reactions to medications like statins and blood thinners. (2)
- Timely Treatment: Enables early detection of genetic risks, reducing the likelihood of severe cardiovascular events. (3)
- Reduce Risk of Complications: Helps lower the chances of complications, such as stroke and arrhythmias.
- Optimize Prevention: Facilitates targeted strategies to manage genetic predispositions, mitigating heart disease risks effectively.
The Impact of Cardiovascular Adverse Drug Reactions and Genetic Insights:
Common cardiovascular drugs, including anticoagulants, contribute to significant treatment costs, with adverse drug reactions (ADRs) accounting for 7.5–22.1% of anticoagulant-related ADRs and 7.0–36.0% for other cardiovascular drugs, leading to complications like bleeding and ICU stays. (1)
Statin-Related ADRs: Indians metabolize statins differently, which can affect drug levels and increase the risk of adverse effects. The SLCO1B1 gene variant is present in around 15% of Indians, leading to statin intolerance. (6)
Clopidogrel Resistance in Indian Patients: Clopidogrel resistance is observed in 15.4% (resistant) and 49.2% (semi-responders) of Indian patients, significantly affecting the drug’s efficacy in preventing cardiovascular events. (5)
Genetic Link to Resistance: The CYP2C19*2 polymorphism, a loss-of-function variant, is a major contributor to clopidogrel resistance, limiting its effectiveness. Identifying such genetic factors through PGx testing can guide alternative therapies for improved treatment outcomes. (5)
3. DrOmics pharmacogenomics test for cardiovascular drugs.
DrOmics Labs’ Comprehensive Cardio PGx Test combines advanced genetic analysis with personalized healthcare to optimize cardiovascular treatment. By evaluating your unique genetic profile, the test provides tailored recommendations on effective medications and dosages, minimizing the risk of adverse drug reactions and enhancing treatment safety and efficacy. Powered by cutting-edge technology, it delivers precise, reliable insights that guide informed decisions for improved heart health. This personalized approach not only ensures better treatment outcomes but also supports long-term cardiovascular well-being through a proactive, science-driven strategy.
| Disease | Drug |
| Acquired Long QT Syndrome (aLQTS) | qt-prolonging drugs |
| iloperidone | |
| Acute coronary syndrome | prasugrel |
| Antiinflammatory agents, non-steroids | |
| aspirin | |
| dalcetrapib | |
| atorvastatin | |
| ticagrelor | |
| clopidogrel | |
| Anemia | morphine |
| peginterferon alfa-2b | |
| docetaxel | |
| bleomycin | |
| Anemia, Hemolytic;Hemolysis | chloramphenicol |
| nitrofurantoin | |
| sulfamethoxazole | |
| ciprofloxacin | |
| methylene blue | |
| phenazopyridine | |
| chloroquine | |
| glyburide | |
| trimethoprim | |
| Anemia, Thrombocytopenia | Platinum compounds |
| Arteriosclerosis | lovastatin |
| Atrial Fibrillation | warfarin |
| apixaban | |
| blood clots and gout attacks. | sulfinpyrazone |
| Blood clots, DVT | dabigatran |
| timolol | |
| isoproterenol | |
| Cardiac Arrest | benzodiazepine derivatives |
| cardiac decompensation | dobutamine |
| Cardiac rhythm disease | propafenone |
| olanzapine | |
| doxorubicin | |
| flecainide | |
| Cardiomyopathies | anthracyclines and related substances |
| cardiotoxicity | cisplatin |
| tramadol | |
| daunorubicin | |
| methotrexate | |
| Cardiovascular Disease | simvastatin |
| amlodipine | |
| HMG CoA reductase inhibitors, other combinations | |
| Chronic Stable Angina | talinolol |
| Coronary Artery Disease | perindopril |
| pravastatin | |
| Ace Inhibitors, Plain | |
| catecholamines | |
| quinapril | |
| hmg coa reductase inhibitors | |
| atenolol | |
| salvianolic acid b | |
| rosuvastatin | |
| deep vein thrombosis and myocardial infarction. | acenocoumarol |
| Essential hypertension | enalapril |
| Calcium channel blockers | |
| benazepril | |
| telmisartan | |
| irbesartan | |
| nitrendipine | |
| heart attack, stroke,cholesterol | fluvastatin |
| Heart Diseases | Antihypertensives |
| Heart Failure | carvedilol |
| spironolactone | |
| Beta Blocking Agents | |
| bucindolol | |
| candesartan | |
| hydralazine / isosorbide dinitrate | |
| diuretics | |
| angiotensin II | |
| Angiotensin II Antagonists | |
| sildenafil | |
| digoxin | |
| Heparin-induced thrombocytopenia | heparin |
| high blood pressure and edema. | Thiazides, plain |
| hyperglycemia | tolbutamide |
| insulin recombinant | |
| zinc acetate | |
| Hyperlipidemias | muraglitazar |
| tacrolimus | |
| hypertension | verapamil |
| nifedipine | |
| metoprolol | |
| hydrochlorothiazide | |
| bisoprolol | |
| losartan | |
| amiloride | |
| hydralazine | |
| imidapril | |
| bevacizumab | |
| ramipril | |
| captopril | |
| chlorothiazide | |
| diltiazem | |
| trandolapril | |
| chlorthalidone | |
| lisinopril | |
| hypertension and edema associated with heart failure | furosemide |
| bumetanide | |
| torasemide | |
| hypertensive disorder | dextromethorphan |
| bufuralol | |
| fentanyl | |
| propofol | |
| remifentanil | |
| sevoflurane | |
| Hypertriglyceridemia | fenofibrate |
| hypotension | ephedrine |
| phenylephrine | |
| myocardial infarction | rifampin |
| propranolol | |
| pitavastatin | |
| Rhabdomyolysis | cerivastatin |
| severe hypertension, renal hypertension | debrisoquine |
| short qt syndrome | disopyramide |
| quinidine | |
| Thrombocytopenia | sorafenib |
| thromboembolic disorders | phenprocoumon |
| coumarin | |
| fluindione | |
| Torsades de Pointes | amiodarone |
| venous thromboembolic event | rivaroxaban |
4. How Does This Work?
- Sample Collection: A saliva or cheek swab sample is collected for DNA extraction.
- Genetic Analysis: The sample undergoes advanced genetic testing to identify markers associated with diabetes medication response.
- Comprehensive Report: A detailed report outlines genetic predispositions, potential drug interactions, and tailored recommendations.
- Expert Consultation: Results are reviewed with a genetic counselor or healthcare provider to develop a personalized diabetes management plan.
Reviews
There are no reviews yet.